Estrogen receptor expression and docetaxel efficacy in patients with metastatic breast cancer: A pooled analysis of four randomized trials

Oncologist

Volumn 15, Issue 5, 2010, Pages 476-483

  Andre, Fabrice ^a,b   Broglio, Kristine ^a   Pusztai, Lajos ^a   Berrada, Narjiss ^b   Mackey, John R ^c   Nabholtz, Jean Marc ^d   Chan, Stephen ^e   Hortobagyi, Gabriel N ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b INSTITUT GUSTAVE ROUSSY   (France)

^c UNIVERSITY OF ALBERTA   (Canada)

^d CENTRE JEAN PERRIN   (France)

^e NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

Breast cancer; Docetaxel; Estrogen receptor; Metastasis

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; MITOMYCIN; VINBLASTINE;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CLINICAL TRIAL; DRUG EFFICACY; DRUG RESPONSE; HUMAN; METASTASIS; MONOTHERAPY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RISK REDUCTION; VISCERAL METASTASIS;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; ESTROGEN RECEPTOR ALPHA; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TAXOIDS;

EID: 77952607491     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2009-0150     Document Type: Article

References (34)

1. Andre F, Slimane K, Bachelot T et al. Breast cancer with synchronous metastases: Trends in survival during a 14-year period. J Clin Oncol 2004;22: 3302-3308.
2. Valero V, Hortobagyi GN. Are anthracycline-taxane regimens the newstandard of care in the treatment of metastatic breast cancer? J Clin Oncol 2003;21:959-962.
3. Lebwohl DE, Canetta R. New developments in chemotherapy of advancedbreast cancer. Ann Oncol 1999;10:(suppl 6):139-146.
4. Bonneterre J, Thurlimann B, Robertson JF et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000;18:3748-3757.
5. Mouridsen H, Gershanovich M, Sun Y et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003;21:2101-2109.
6. Marty M, Cognetti F, Maraninchi D et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: The M77001 study group. J Clin Oncol 2005;23:4265-4274.
7. Bonneterre J, Buzdar A, Nabholtz JM et al.; Arimidex Writing Committee; Investigators Committee Members. Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001;92:247-2258.
8. Stockler M, Wilcken NR, Ghersi D et al. Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treat Rev 2000;26:151-168.
9. Kataja VV, Colleoni M, Bergh J.; ESMO Guidelines Task Force. ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of locally recurrent or metastatic breast cancer (MBC). Ann Oncol 2005; 16(suppl 1):i10-il2.
10. Beslija S, Bonneterre J, Burstein H et al. Second consensus on medical treatment of metastatic breast cancer. Ann Oncol 2007;18:215-225.
11. Bear HD, Anderson S, Brown A et al.; National Surgical Adjuvant Breast and Bowel Project Protocol B-27. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: Preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003;21:4165-4174.
12. Andre F, Broglio K, Roche H et al. Estrogen receptor expression and efficacy of docetaxel-containing adjuvant chemotherapy in patients with nodepositive breast cancer: Results from a pooled analysis. J Clin Oncol 2008; 26:2636-2643.
13. Chan S, Friedrichs K, Noel D et al.; 303 Study Group. Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer. J Clin Oncol 1999;17:2341-2354.
14. Nabholtz JM, Senn HJ, Bezwoda WR et al. Prospective randomized trial of Andre, Broglio, Pusztai et al. docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing che-motherapy. 304 Study Group. J Clin Oncol 1999;17:1413-1424.
15. Nabholtz JM, Falkson C, Campos D et al.; TAX 306 Study Group. Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: Results of a randomized, multicenter, phase III trial. J Clin Oncol 2003;21:968-975.
16. Mackey JR, Paterson A, Dirix LY. Final results of the phase III randomized trial comparing docetaxel (T), doxorubicin (A) and cyclophosphamide (C) to FAC as first line chemotherapy for patients with metastatic breast cancer [abstract 137]. Proc Am Soc Clin Oncol 2002;21:35a.
17. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981;47:207-214.
18. Harris LN, Broadwater G, Lin NU et al. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: Results from CALGB 9342. Breast Cancer Res 2006;8:R66.
19. Rosner D, Lane WW, Nemoto T. Differential response to chemotherapy in metastatic breast cancer in relation to estrogen receptor level. Results of a prospective randomized study. Cancer 1989;64:6-15.
20. Van Poznak C, Tan L, Panageas KS et al. Assessment of molecular markers of clinical sensitivity to single-agent taxane therapy for metastatic breast cancer. J Clin Oncol 2002;20:2319-2326.
21. Bennett JM, Muss HB, Doroshow JH et al. A randomized multicenter trial comparing mitoxantrone, cyclophosphamide, and fluorouracil with doxorubicin, cyclophosphamide, and fluorouracil in the therapy of metastatic breast carcinoma. J Clin Oncol 1988;6:1611-1620.
22. Sjoˆstro¨m J, Krajewski S, Franssila K et al. A multivariate analysis of tumour biological factors predicting response to cytotoxic treatment in advanced breast cancer. Br J Cancer 1998;78:812-815.
23. Alexandre J, Bleuzen P, Bonneterre J et al. Factors predicting for efficacy and safety of docetaxel in a compassionate-use cohort of 825 heavily pretreated advanced breast cancer patients. J Clin Oncol 2000;18:562-573.
24. Paik S, Tang G, Shak S et al. Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 2006;24:3726-3734.
25. Rouzier R, Perou CM, Symmans WF et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11:5678-5685.
26. Tordai A, Wang J, Andre F et al. Evaluation of biological pathways involved in chemotherapy response in breast cancer. Breast Cancer Res 2008; 10:R37.
27. Hugh J, Hanson J, Cheang MC et al. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: Use of an immunohistochemical definition in the BCIRG 001 trial. J Clin Oncol 2009;27:1168-1176
28. Cole BF, Gelber RD, Gelber S et al. Polychemotherapy for early breast cancer: An overview of the randomised clinical trials with quality-adjusted survival analysis. Lancet 2001;358:277-286.
29. Adjuvant Breast Cancer Trials Collaborative Group. Polychemotherapy for early breast cancer: Results from the international adjuvant breast cancer chemotherapy randomized trial. J Natl Cancer Inst 2007;99:506-515.
30. Di Leo A, Bleiberg H, Buyse M. Overall survival is not a realistic end point for clinical trials of new drugs in advanced solid tumors: A critical assessment based on recently reported phase III trials in colorectal and breast cancer. J Clin Oncol 2003;21:2045-2047.
31. Albain K, Barlow W, O'Malley F et al. Concurrent versus sequential chemohormonal therapy versus T alone for postmenopausal, node-positive, estrogen and/or progesterone receptor-positive breast cancer: Mature outcomesandnewbiologiccorrelatesonphaseIIIintergrouptrial0100[abstract 37]. Presented at the 27th Annual San Antonio Breast Cancer Sym-posium, San Antonio, TX, December 8-11, 2004.
32. Goldhirsch A, Glick JH, Gelber RD et al. Meeting highlights: International expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 2005;16:1569-1583.
33. Pusztai L, Broglio K, Andre F et al. Effect of molecular disease subsets on disease-free survival in randomized adjuvant chemotherapy trials for estrogen receptor-positive breast cancer. J Clin Oncol 2008;26:4679-4683.
34. Hess KR, Anderson K, Symmans WF et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 2006; 24:4236-4244.